|
|
|
|
|
|
|
|
|
27.08.25 - 10:15
|
Sanofi Hold (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Sanofi mit einem Kursziel von 90 Euro auf "Hold" belassen. Dies schrieb Analyst Emmanuel Papadakis in seiner am Mittwoch vorliegenden Auswertung der wöchentlichen Verschreibungsdaten./ag/ajxVeröffentlichung ......
|
|
|
|
|
27.08.25 - 08:09
|
Sanofi Buy (DPA-AFX)
|
|
|
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Sanofi mit einem Kursziel von 115 Euro auf "Buy" belassen. Nach jüngsten Forschungsmisserfolgen seien die Anleger enorm nervös vor den anstehenden Phase-3-Daten zum Antikörper ......
|
|
|
22.08.25 - 18:39
|
Saudi Arabia Diabetes Drug Market Trends and Company Analysis Report 2025-2033 Featuring Novo Nordisk, AstraZeneca, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Novartis - ResearchAndMarkets.com (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--The "Saudi Arabia Diabetes Drug Market Trends & Forecast 2025-2033" report has been added to ResearchAndMarkets.com's offering.
The Saudi Arabia Diabetes Drug Market is anticipated to grow to US$ 1.33 billion by 2033, from US$ 773.6 million in 2024, growing at a CAGR of 6.22% from 2025 to 2033
This growth is due to an increase in the prevalence of diabetes, enhanced awareness, government healthcare expenditure, and acceptance of new therapeutic agents like SGLT2 inhibitors, GLP-1 receptor agonists, and biosimilar insulins.
Diabetes medication in Saudi Arabia is experiencing growing popularity because of the prevalence of diabetes, which is largely caused by sedentary lifestyles, eating habits, and obesity. Strategic government efforts, such as Vision 2030, focus on enhanced access to healthcare and chronic disease management. The increasing number of diabetics, heightened awareness, and upgraded diagnostic facilities are driving demand for traditional as well as advanced treatmen...
|
|
|
21.08.25 - 13:06
|
Leaders Come Together to Advance the Industry at Veeva Summit (PR Newswire)
|
|
|
Alnylam Pharmaceuticals, BeOne Medicines, Intercept Pharmaceuticals, Merck, Pfizer, and Sanofi among biopharmas sharing strategies that set future direction Veeva to showcase innovations, including deep industry-specific Veeva AI in Vault Platform and Veeva applications PLEASANTON,......
|
|
|
|
|
|
|
|
|
|
|
|
|
13.08.25 - 16:54
|
Sanofi Aktie: Kein schlechter Zeitpunkt (Aktiencheck)
|
|
|
Wien (www.aktiencheck.de) - Sanofi-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), stuft in einer aktuellen Aktienanalyse die Aktie der Sanofi S.A. (ISIN: FR0000120578, WKN: 920657, Ticker-Symbol: SNW, Euronext Paris-Symbol: SAN, NASDAQ OTC-Symbol: SNYNF) von "Halten" auf "Kauf" hoch. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
